With the greatly accelerated review and approval speed, and the market entry rules being clearer, especially influenced by the COVID-19 pandemic, the clinical demand for biotherapeutic products has become increasingly urgent. Therefore, biotherapeutic products have become a very important part impacting the world economy. However, opportunities and challenges coexist. For instance, the therapies developed are too concentrated on several popular targets, costs are too high, it is difficult to maintain quality consistency, and there lacks uniform quality standards for new treatment methods. These problems are not only faced by a certain biotech company, but are also needed to be overcome by the Chinese biopharmaceutical industry. 

As the annual event with the highest participation rate of the Chinese biopharmaceutical companies, the 8th BioCon 2021 will be held at Shanghai Marriott Hotel Parkview on April 22-23, 2021. BioCon 2021 will have an in-depth analysis on the next-generation bispecific/polyclonal antibodies, ADCs, cell and gene therapy products, oncolytic virus products, nucleic acid vaccines and drugs. It will also focus on exploring the latest regulatory trends and the cutting-edge development strategies of biotherapeutics, from new drug discovery and design, intelligent/continuous/automated process development and optimization, cost reduction and efficiency enhancement to commercialization and market entry of biotherapeutics. This comprehensive analysis intends to build a professional and high-quality platform for domestic and foreign companies to discuss policies, exchange technologies, display products and develop businesses. BioCon 2021 aims to fully promote the development of the biopharmaceutical industry!